Instytut Hematologii I Transfuzjologii

At Instytut Hematologii I Transfuzjologii in Warsaw, a large share of the clinical research focuses on hematologic diseases and neoplasms, especially blood cancers such as acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and lymphomas. These studies are designed to assess new treatment options, compare active therapies, and improve outcomes for patients with relapsed or hard-to-treat disease.

• Research in acute leukemias, including AML and ALL, with an emphasis on better disease control and response assessment
• Trials in lymphomas such as follicular lymphoma, mantle cell lymphoma, Hodgkin lymphoma, and diffuse large B-cell lymphoma
• Studies in multiple myeloma and related plasma cell disorders to improve treatment effectiveness and deepen remission
• Investigations in chronic lymphocytic leukemia and other mature B-cell malignancies, often comparing newer targeted therapies

Overall, the site supports a broad portfolio of blood cancer trials aimed at testing innovative therapies and refining treatment strategies across several difficult-to-treat conditions.

Another major research area at this laboratory and research facility is myeloid malignancies, including myelofibrosis, myelodysplastic syndromes, and related precursor conditions. The trials explore whether new therapies can better control symptoms, reduce spleen enlargement, and improve blood counts in patients with chronic bone marrow disorders.

• Studies in myelofibrosis, including primary disease and forms that develop after other blood disorders
• Research in myelodysplastic syndromes and higher-risk precancerous marrow conditions
• Trials in acute myeloid leukemia linked to specific molecular subtypes or prior treatment resistance
• Work focused on evaluating treatment benefit, symptom relief, and disease response in myeloid cancers

The research here reflects a strong interest in improving care for patients with complex marrow diseases, especially where standard options may be limited.

The site also conducts important studies in hematology related to bleeding disorders and thrombotic diseases. These trials include inherited and acquired conditions such as hemophilia, thrombotic thrombocytopenic purpura, and von Willebrand disease, with a focus on prevention, safety, and better long-term disease control.

• Trials in hemophilia A and hemophilia B, including patients with or without inhibitors
• Studies in thrombotic thrombocytopenic purpura, both immune-mediated and congenital forms
• Research on von Willebrand disease and other rare bleeding conditions
• Evaluation of prophylactic approaches to reduce bleeding episodes and improve everyday safety

These investigations support better preventive care for people living with rare and sometimes life-threatening disorders of clotting and blood vessel health.

Clinical research at Instytut Hematologii I Transfuzjologii also extends to immune system diseases and conditions involving abnormal immune or complement activity. The main focus is on paroxysmal nocturnal hemoglobinuria, immune thrombocytopenia, and related disorders, with trials aimed at improving disease control and reducing harmful immune-driven effects.

• Studies in paroxysmal nocturnal hemoglobinuria evaluating new ways to control hemolysis and transfusion needs
• Research in immune thrombocytopenia and thrombotic thrombocytopenic purpura to improve safety and blood count stability
• Trials addressing immune dysfunction in patients with chronic lymphocytic leukemia
• Work exploring long-term effectiveness and tolerability of treatments for chronic immune-mediated blood disorders

This area highlights the site’s role in testing therapies that target the immune system more precisely for patients with rare hematologic conditions.

Beyond disease-specific treatment studies, the site is active in cell therapy, transplant-related care, and supportive approaches for patients with blood cancers. Research includes follow-up after genetically modified T-cell treatment, transplant-adjacent strategies, and efforts to reduce treatment-related complications such as infection or cardiac injury.

• Long-term follow-up of patients treated with genetically modified T cells
• Studies supporting patients undergoing hematopoietic stem cell transplantation or cancer therapy around transplant
• Trials aimed at preventing complications such as infection and cardiotoxicity
• Research on maintaining safety, durability of response, and quality of care after intensive treatment

These studies broaden the research portfolio at the Warsaw site by addressing both advanced therapies and the practical challenges of long-term cancer care.

The clinical trial program also includes selected studies in rare genetic and metabolic diseases, showing the site’s wider interest in specialized medicine. These trials involve conditions such as erythropoietic protoporphyria, X-linked protoporphyria, and hereditary iron overload disorders, with the goal of improving symptoms, safety, and day-to-day functioning.

• Research in erythropoietic protoporphyria and X-linked protoporphyria focused on reducing light sensitivity symptoms
• Studies in hereditary hemochromatosis and other uncommon inherited conditions
• Trials addressing symptom relief and longer-term disease management in rare disorders
• Evaluation of treatment benefit in patients with limited therapeutic options

These projects complement the site’s main hematology portfolio by extending research into uncommon diseases that still require better treatment solutions.